Skip to main content
SpringerLink
Log in

Eptifibatide-induced thrombocytopenia

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-year-old man presenting with a non ST-elevation myocardial infarction (NSTEMI) who underwent primary PCI with stenting and developed stent thrombosis 5 days after the procedure. He underwent repeat PCI with readministration of eptifibatide and subsequently developed profound thrombocytopenia within 4 h. This report adds another case of eptifibatide associated thrombocytopenia to the literature and reinforces the importance of platelet count monitoring after therapy with this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Coller BS (1990) Platelets and thrombolytic therapy. N Engl J Med 322(1):33–42

    Article  PubMed  CAS  Google Scholar 

  2. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E (1986) Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231(4745):1559–1562

    Article  PubMed  CAS  Google Scholar 

  3. Topol EJ, Ferguson JJ,Weisman HF, Tcheng JE, Ellis SG, Kleiman NS et al (1997) Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 278(6):479–484

    Article  PubMed  CAS  Google Scholar 

  4. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339(7):436–443

    Article  Google Scholar 

  5. Carborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM et al (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266(15):9359–9362

    Google Scholar 

  6. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC et al (2001) Abciximab readministration: results of the ReoPro readministration registry. Circulation 104(8):870–875

    Article  PubMed  CAS  Google Scholar 

  7. Jubelirer SJ, Koenig BA, Bates MC (1999) Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 61(3):205–208

    Article  PubMed  CAS  Google Scholar 

  8. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L (2004) Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol 93(4):453–455

    Article  PubMed  CAS  Google Scholar 

  9. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ et al (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344(25):1888–1894

    Article  PubMed  CAS  Google Scholar 

  10. The IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet 349(9063):1422–1428

  11. O’Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM et al (2001) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 285(19):2468–2473

    Article  PubMed  CAS  Google Scholar 

  12. Epelman S, Nair D, Downey R, Militello M, Askari A (2006) Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 22:151–154

    Article  PubMed  CAS  Google Scholar 

  13. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH (2003) Eptifibatide induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 58(1):76–79

    Article  PubMed  Google Scholar 

  14. Coons JC, Barcelona RA, Freedy T, Hagerty MF (2005) Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 39(2):368–372

    Article  PubMed  Google Scholar 

  15. Salengro E, Mulvihill NT, Farah B (2003) Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv 58(1):73–75

    Article  PubMed  Google Scholar 

  16. Yoder M, Edwards RF (2002) Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 36(4):628–630

    Article  PubMed  Google Scholar 

  17. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH (2003) Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 1(2):392–394

    Article  PubMed  CAS  Google Scholar 

  18. Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P (2003) Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 23(3):374–379

    Article  PubMed  Google Scholar 

  19. Khaykin Y, Paradiso-Hardy FL, Madan M (2003) Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol 19(7):797–801

    PubMed  CAS  Google Scholar 

  20. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S et al (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100(6):2071–2076

    PubMed  CAS  Google Scholar 

  21. Jennings LK, Haga JH, Slack SM (2000) Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 84(6):1095–1102

    PubMed  CAS  Google Scholar 

  22. Hayward CP (2004) Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibodymediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia. Thromb Haemost 92(4):674–675

    PubMed  CAS  Google Scholar 

  23. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99(6):2054–2059

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, Scaife Hall, Suite S553, Pittsburgh, PA, 15213, USA

    Marwan Refaat, A. J. Conrad Smith & Daniel Edmundowicz

Authors
  1. Marwan Refaat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. J. Conrad Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Edmundowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marwan Refaat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Refaat, M., Smith, A.J.C. & Edmundowicz, D. Eptifibatide-induced thrombocytopenia. J Thromb Thrombolysis 25, 204–206 (2008). https://doi.org/10.1007/s11239-007-0166-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0166-x

Keywords

Search

Navigation